A decision support system for the identification of metastases of Metastatic Melanoma using whole-body FDG PET/CT images.

Metastatic Melanoma (MM) is an aggressive type of cancer which produces metastases throughout the body with very poor survival rates. Recent advances in immunotherapy have shown promising results for controlling disease's progression. Due to the often rapid progression, fast and accurate diagnosis and treatment response assessment is vital for the whole patient management. These procedures prerequisite accurate, whole-body tumor identification. This can be offered by the imaging modality Positron Emission Tomography (PET)/Computed Tomography (CT) with the radiotracer F 18-Fluorodeoxyglucose (FDG). However, manual segmentation of PET/CT images is a very time-consuming and labor intensive procedure that requires expert knowledge. Most of the previously published segmentation techniques focus on a specific type of tumor or part of the body and require a great amount of manually labeled data, which is, however, difficult for MM. Multimodal analysis of PET/CT is also crucial because FDG-PET contains only the functional information of tumors which can be complemented by the anatomical information of CT. In this paper, we propose a whole-body segmentation framework capable of efficiently identifying the highly heterogeneous tumor lesions of MM from the whole-body 3D FDG-PET/CT images. The proposed decision support system begins with an Ensemble Unsupervised Segmentation of regions of high FDG-uptake based on Fuzzy C-means and a custom region growing algorithm. Then, a region classification model based on radiomics features and Neural Networks classifies these regions as tumors or not. Experimental results showed high performance in the identification of MM lesions with Sensitivity 83.68%, Specificity 91.82%, F1-score 75.42%, AUC 94.16% and Balanced accuracy 87.75% which were also supported by the public dataset evaluation.